Neurocrine Biosciences (NBIX) Other Working Capital Changes (2010 - 2026)

Neurocrine Biosciences has reported Other Working Capital Changes for 17 years, with the latest figure at $31.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 4385.71% year-over-year to $31.4 million; the trailing twelve-month figure through Mar 2026 stood at $75.1 million (up 46.39% YoY), and the FY2025 full-year result was $44.4 million, down 17.78% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $31.4 million, up from $27.8 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $54.0 million in Q4 2024, with the low at -$24.6 million in Q2 2023.
• Historically, Other Working Capital Changes has averaged $9.2 million across 5 years, with a median of $2.4 million in 2022.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes sank 1740.0% — and 2026, when it jumped 4385.71%.
• Neurocrine Biosciences' Other Working Capital Changes stood at $14.2 million in 2022, then slumped by 121.83% to -$3.1 million in 2023, then soared by 1841.94% to $54.0 million in 2024, then sank by 48.52% to $27.8 million in 2025, then climbed by 12.95% to $31.4 million in 2026.
• The last three Other Working Capital Changes figures came in at $31.4 million (Q1 2026), $27.8 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.